S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
Log in
NASDAQ:CORT

Corcept Therapeutics Stock Forecast, Price & News

$17.41
-0.14 (-0.80 %)
(As of 09/30/2020 04:30 PM ET)
Add
Compare
Today's Range
$17.27
Now: $17.41
$17.98
50-Day Range
$12.46
MA: $15.90
$19.98
52-Week Range
$9.70
Now: $17.41
$23.48
Volume1.06 million shs
Average Volume1.68 million shs
Market Capitalization$2.01 billion
P/E Ratio18.52
Dividend YieldN/A
Beta0.98
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer; CORT118335 selective cortisol modulator for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Read More
Corcept Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.79 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:CORT
CUSIP21835210
Phone650-327-3270

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$306.49 million
Cash Flow$0.86 per share
Book Value$3.25 per share

Profitability

Net Income$94.18 million

Miscellaneous

Employees166
Market Cap$2.01 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$17.41
-0.14 (-0.80 %)
(As of 09/30/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

How has Corcept Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Corcept Therapeutics' stock was trading at $10.95 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CORT shares have increased by 59.0% and is now trading at $17.41.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Corcept Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Corcept Therapeutics
.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Corcept Therapeutics
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Tuesday, August, 4th. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. The biotechnology company had revenue of $88.60 million for the quarter, compared to analysts' expectations of $90.13 million. Corcept Therapeutics had a net margin of 32.49% and a return on equity of 29.10%. The firm's revenue for the quarter was up 23.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.25 earnings per share.
View Corcept Therapeutics' earnings history
.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $355-375 million, compared to the consensus revenue estimate of $368.27 million.

What price target have analysts set for CORT?

2 Wall Street analysts have issued 1 year price objectives for Corcept Therapeutics' stock. Their forecasts range from $15.00 to $16.00. On average, they expect Corcept Therapeutics' stock price to reach $15.50 in the next twelve months. This suggests that the stock has a possible downside of 11.0%.
View analysts' price targets for Corcept Therapeutics
.

Are investors shorting Corcept Therapeutics?

Corcept Therapeutics saw a decline in short interest in September. As of September 15th, there was short interest totaling 18,860,000 shares, a decline of 18.6% from the August 31st total of 23,160,000 shares. Based on an average daily volume of 2,890,000 shares, the days-to-cover ratio is presently 6.5 days. Approximately 18.1% of the shares of the company are short sold.
View Corcept Therapeutics' Short Interest
.

Who are some of Corcept Therapeutics' key competitors?

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Pfizer (PFE), Inovio Pharmaceuticals (INO) and Netflix (NFLX).

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the following people:
  • Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 62)
  • Mr. Gary Charles Robb, CFO & Sec. (Age 56)
  • Mr. Sean Maduck, Sr. VP of Commercial (Age 42)
  • Dr. Christopher Shayne James M.D., Director of Investor Relations
  • Dr. Hazel Hunt Ph.D., Sr. VP of Research

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $17.41.

How big of a company is Corcept Therapeutics?

Corcept Therapeutics has a market capitalization of $2.01 billion and generates $306.49 million in revenue each year. The biotechnology company earns $94.18 million in net income (profit) each year or $0.77 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is www.corcept.com.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.